Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BioCryst Pharmaceuticals Inc BCRX

Healthcare Biotechnology
BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of... see more

Recent & Breaking News (NDAQ:BCRX)

BioCryst Receives Positive Opinion on European Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema

GlobeNewswire January 14, 2015

BioCryst to Present at J.P. Morgan Healthcare Conference

GlobeNewswire January 6, 2015

BioCryst Pharmaceuticals Announces the Appointment of Lynne Powell as Chief Commercial Officer

GlobeNewswire January 5, 2015

BioCryst Receives Orphan Drug Designation for BCX4161 for the Treatment of Hereditary Angioedema

GlobeNewswire December 23, 2014

BioCryst Announces Study Results for BCX4430 in a Non-Human Primate Model of Ebola Virus Infection

GlobeNewswire December 23, 2014

BioCryst's RAPIVAB(TM) (peramivir injection) Receives FDA Approval for the Treatment of Acute Uncomplicated Influenza

GlobeNewswire December 22, 2014

BioCryst Initiates OPuS-2: A Clinical Trial of BCX4161 in Patients With Hereditary Angioedema

GlobeNewswire December 18, 2014

BioCryst Announces Initiation of a Phase 1 Clinical Trial of BCX4430 for the Treatment of Hemorrhagic Fever Viruses

GlobeNewswire December 15, 2014

BioCryst to Present at Two Upcoming Investor Conferences

GlobeNewswire November 20, 2014

BioCryst Reports Third Quarter 2014 Financial Results

GlobeNewswire November 6, 2014

BioCryst to Announce Third Quarter 2014 Financial Results November 6

GlobeNewswire October 30, 2014

RAPIVAB(TM) Trial Results for the Treatment of Influenza to be Presented at IDWeek 2014

GlobeNewswire October 8, 2014

BioCryst Announces Late Breaker Presentation of OPuS-1 Phase 2 Trial Results at the 23rd EADV Congress

GlobeNewswire October 7, 2014

BioCryst Receives Additional NIAID Funding for Manufacture and Development of BCX4430 to Treat Hemorrhagic Virus Diseases

GlobeNewswire September 18, 2014

BioCryst Pharmaceuticals Inc. (BCRX) Jumps 5.52% on September 10

Equities.com September 10, 2014

BioCryst Announces RAPIVAB(TM) Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

GlobeNewswire September 6, 2014

BioCryst Participates in World Health Organization Consultation on Potential Ebola Therapies

GlobeNewswire September 4, 2014

BioCryst to Present at Rodman & Renshaw Conference

GlobeNewswire September 3, 2014

BioCryst to Present Peramivir Trial Results for the Treatment of Influenza at the ICAAC 2014 Meeting

GlobeNewswire September 2, 2014

BioCryst Receives Additional NIAID Funding to Conduct a Non-Human Primate Study of BCX4430 in Ebola Virus Disease

GlobeNewswire August 29, 2014